Leukemias

Every leukemia is sorted twice: by speed and by lineage. Speed is decided by a single number. "Blasts, which are immature and dysfunctional cells, normally make up 1% to 5% of marrow cells. Acute leukemias are characterized by greater than 20% blasts on peripheral blood smear or bone marrow, leading to a more rapid onset of symptoms. In contrast, chronic leukemia has less than 20% blasts." Lineage splits myeloid from lymphoid. Cross the two axes and you have the four diseases.

ALL — acute lymphoblastic leukemia is a malignancy of immature B or T lymphoblasts, and it is "the most common leukemia in the pediatric population, accounting for up to 80% of cases in this group vs 20% of cases in adults," peaking between ages two and ten. AML — acute myeloid leukemia is "the most common acute leukemia in adults… the most aggressive cancer with a variable prognosis," a clonal expansion of primitive hematopoietic stem cells, with a median age at diagnosis of about 68. CLL — chronic lymphocytic leukemia is "a monoclonal lymphoproliferative disease" of dysfunctional B cells; "most cases occur in people aged 60 to 70," and it "is considered an indolent disease." CML — chronic myelogenous leukemia is a myeloproliferative neoplasm of proliferating granulocytes driven by "reciprocal translocation and fusion of BCR on chromosome 22 and ABL1 on chromosome 9" — the Philadelphia chromosome.

That single translocation is worth dwelling on, because it explains why one leukemia has a targeted cure. The fusion produces a "dysregulated tyrosine kinase," driving proliferation. One always-on enzyme means one drug can switch it off — and CML became one of the first cancers "revolutionized by utilizing targeted therapy with Ph chromosome targeting TKIs." CML also shows the two axes are a spectrum rather than a wall: blast phase is defined at 20% or more blasts, which is chronic leukemia turning into acute leukemia — and the WHO 2022 classification no longer requires a separate accelerated phase, which older schemes set at 10 to 19% blasts.

And the presentations differ as sharply as the biology. Acute leukemia presents fast and loudly — "fever, lethargy, and bleeding," with AML onset "relatively rapid, often on the order of days to weeks." Chronic leukemia often presents silently: "many patients are asymptomatic at the time of diagnosis, identified only incidentally after marked leukocytosis is discovered on a complete blood count." About half of CML patients and many CLL patients have no symptoms at all when diagnosed.

Almost everything a nurse does for a leukemia patient traces back to one sentence: malignant cells undergo "clonal expansion and proliferation, leading to replacement and interference with the development and function of normal blood cells." The marrow is a finite space with a finite output, and the leukemic clone takes it over. Three consequences follow immediately and in parallel. Anemia from red blood cell replacement produces fatigue, weakness, pallor, dyspnea and chest tightness. Infection risk from reduced functional white blood cells produces fever and recurrent infection. Bleeding from platelet reduction and dysfunction produces easy bruising, petechiae and mucosal bleeding. One mechanism, three problems — which is why the classic presentation is all three at once rather than any of them alone.

The cruel paradox of this disease is that the white-cell count is a liar. Blasts are "immature and dysfunctional cells," so a patient can have a strikingly high white-cell count and be profoundly immunosuppressed at the same time. A leukocytosis here is not immunity — it is the tumour. This is the reason the absolute neutrophil count, not the white-cell count, governs every infection decision on the unit.

Two further mechanisms explain findings that otherwise look unrelated. Organomegaly arises as leukemic cells infiltrate the spleen, liver and lymph nodes — the spleen is doing its job and choking on the volume. In the chronic leukemias, splenomegaly becomes a mass-effect problem, with early satiety among the presenting symptoms. Bone pain, especially "involving the spine and long bones," comes from marrow expansion pressing outward on the periosteum — which is why a child with leukemia may present limping rather than febrile.

One subtype runs on a completely different clock. Acute promyelocytic leukemia (APL), defined by the PML::RARA fusion gene, is a coagulation emergency at presentation: the malignant cells themselves drive the coagulopathy. The result is disseminated intravascular coagulation, and APL patients "typically present with bleeding diathesis with increased coagulation parameters (elevated PT, aPTT) and low fibrinogen." That is why it is "important to start the treatment with ATRA (all-trans-retinoic acid) when APL is suspected rather than awaiting confirmatory tests with FISH" — one of the few cancer drugs started before the diagnosis is proven.

Because the white-cell count is unreliable, the working number is the absolute neutrophil count, and it is calculated rather than reported: ANC = WBC (cells/microL) × percent (PMNs + bands) / 100. Segmented neutrophils and bands both count, because both can fight infection. Learn the formula rather than looking for the value on the panel — on many reports it is not there.

The severity ladder runs: normal circulating neutrophils above 1.5 × 10⁹/L; mild 1.0 to 1.5 × 10⁹/L; moderate 0.5 to 1.0 × 10⁹/L; severe below 0.5 × 10⁹/L; agranulocytosis below 0.2 × 10⁹/L. The clinical inflection is stated plainly: "once the neutrophil count is below 1.5 × 10⁹/L, recurrent infections become more common." One physiologic caveat keeps this honest — circulating neutrophils represent only 3 to 5% of total body neutrophils, so adequate marrow reserve can mitigate the risk even when the peripheral count looks alarming.

Febrile neutropenia is where those numbers become an emergency protocol, and the standard definition sets both halves. Fever is "a single oral temperature greater than or equal to 101 F (38.3 C) or a temperature greater than or equal to 100.4 F (38 C) for at least an hour." Neutropenia is an ANC below 500 cells/µL — or, in the NCCN definition, one expected to fall to 500 or below within the next 48 hours — and "in profound neutropenia, the ANC is less than 100 cells/microliter." Read the temperature criterion carefully — one reading at 38.3 °C is enough, or a lower 38.0 °C sustained for an hour. And read the ANC criterion carefully too: it is forward-looking, so a patient whose count is 700 and falling on day 8 of induction qualifies before it ever reaches 500.

A discrepancy worth knowing about. Some secondary summaries print 1,500 cells/µL inside this definition. The NCCN definition uses 500, and 500 is the number institutional protocols and examinations are built on. The 1,500 figure belongs to a different question — it is the general neutropenia threshold, the point at which "recurrent infections become more common" on the severity ladder above. Keep the two in separate lanes: 1,500 tells you the patient is neutropenic; 500 tells you a fever is febrile neutropenia.

Then the clock starts. Intravenous antibiotics are given "within 1 hour after triage" for high-risk patients, and the clock runs from triage, not from the decision. Work happens in parallel rather than in sequence: "two sets of blood cultures should be obtained from a peripheral vein and any venous catheters," plus urinalysis, throat cultures, and chest imaging if there are respiratory symptoms — but cultures must not delay the antibiotic. Empiric therapy per the IDSA, as reported by StatPearls, is "monotherapy with antipseudomonal beta-lactam agents such as cefepime, carbapenems, or piperacillin/tazobactam" — the regimen must cover Pseudomonas. About 30% of episodes have a documented infection, most bacterial, with gram-positive organisms now most common in roughly a 60:40 ratio. Risk is stratified by the MASCC score: "patients with a score greater than 21 are considered low risk, and less than 21 are high risk," and low-risk patients may take oral therapy.

Neutropenic precautions are among the most confidently taught rules in nursing and among the least uniformly evidenced. Most of the specific rules come from one document — the CDC’s guidelines for preventing opportunistic infections in hematopoietic stem cell transplant recipients, written with the IDSA and the American Society for Blood and Marrow Transplantation — and they are widely applied to other profoundly neutropenic patients, including leukemia patients in induction. Two things follow. The rules carry evidence grades, and the grade is worth reading: an A is a strong recommendation, and a roman III means the evidence is expert opinion rather than trials. And strictly, their population is the transplant recipient, so each rule below is labelled with the population it was written for. What follows is what the sources do and do not support.

Strongly supported. Hand hygiene is the foundation — "Hand washing is the single-most critical and effective procedure for preventing nosocomial infection," and it applies to everyone who enters the room; patient education for neutropenia centres on "rigorous handwashing and using masks when appropriate." Oral care is a real intervention rather than a comfort measure: the CDC transplant guidance calls for "oral rinses 4–6 times/day with sterile water, normal saline, or sodium bicarbonate solutions" in patients with mucositis, and says patients "should brush their teeth ≥2 times/day with a soft regular toothbrush," with an ultrasoft toothbrush or toothette if that cannot be tolerated. Central lines follow published guidelines for preventing intravascular device-related infections. And visitor screening matters: the same guidance bars visitors with "URIs, flu-like illnesses, recent exposure to communicable diseases, an active shingles rash whether covered or not, a VZV-like rash within 6 weeks of receiving a live-attenuated VZV vaccine, or a history of receiving an oral polio vaccine within the previous 3–6 weeks."

Supported, with the caveat attached. The flowers rule comes from the transplant guidance, and it states its own caveat: "exposure to plants and flowers has not been conclusively reported to cause fungal infections among HSCT recipients," yet "most researchers strongly recommend that plants and dried or fresh flowers should not be allowed in the rooms" (B-III), because Aspergillus has been isolated from potted plants and flower arrangements. Single rooms and filtration have different grades: "HSCT recipients should be placed in private (i.e., single-patient) rooms (BIII)," while "All allogeneic recipients should be placed in rooms with >12 air exchanges/hour" and point-of-use HEPA filters (A-III) — a rule written for allogeneic transplant recipients, not for every neutropenic patient. The rectal rule is also transplant guidance: "the use of rectal thermometers, enemas, suppositories, and rectal exams are contraindicated among HSCT recipients to avoid skin or mucosal breakdown," and "menstruating immunocompromised HSCT recipients should not use tampons." It is widely applied to profoundly neutropenic patients and remains standard practice, but it is graded D-III — expert opinion — so the certainty with which it is taught outruns its evidence.

And then the one that does not work at all. The neutropenic diet — also called the low-bacterial or low-germ diet — dates from the 1960s and typically excludes "fresh fruit and vegetables, some types of cheese, uncooked meat, fish and eggs, as well as unpasteurized dairy products." A 2025 systematic review of five randomized controlled trials and 510 adult patients concluded: "An ND does not have a beneficial effect on infection rates, GI health, mortality or hospitalisation length for haemato-oncological patients" — and worse, "an ND tends to negatively affect the patient’s nutritional status; therefore, an adaption in clinical routine should take place." Yet over 90% of centres in 23 countries still use one. That gap between evidence and practice is worth naming out loud, because a student who meets a neutropenic diet on placement should understand what they are looking at. What genuinely replaces it is ordinary food safety — avoiding raw or undercooked foods and unpasteurized products.